A Vaccine Consisting of Recombinant Borrelia burgdorferi Outer-Surface Protein A to Prevent Lyme Disease
Leonard H. Sigal, M.D., John M. Zahradnik, M.D., Philip Lavin, Ph.D., Sondra J. Patella, M.S.N., N.P.-C., Gary Bryant, M.D., Ray Haselby, D.O., Eileen Hilton, M.D., Mark Kunkel, M.D., Debra Adler-Klein, M.D., Terrence Doherty, M.D., Janine Evans, M.D., Stephen E. Malawista, M.D., Philip J. Molloy, M.D., Adam L. Seidner, M.D., M.P.H., James R. Sabetta, M.D., Henry J. Simon, M.D., Mark S. Klempner, M.D., John Mays, and Donald Marks, M.D.
Background Lyme disease is a multisystem inflammatory diseasecaused by infection with the tick-borne spirochete Borreliaburgdorferi and is the most common vector-borne infection inthe United States. We assessed the efficacy of a recombinantvaccine consisting of outer-surface protein A (OspA) withoutadjuvant in subjects at risk for Lyme disease.
Methods For this double-blind trial, 10,305 subjects 18 yearsof age or older were recruited at 14 sites in areas of the UnitedStates where Lyme disease was endemic; the subjects were randomlyassigned to receive either placebo (5149 subjects) or 30 µgof OspA vaccine (5156 subjects). The first two injections wereadministered 1 month apart, and 7515 subjects also receiveda booster dose at 12 months. The subjects were observed fortwo seasons during which the risk of transmission of Lyme diseasewas high. The primary end point was the number of new clinicallyand serologically confirmed cases of Lyme disease.
Results The efficacy of the vaccine was 68 percent in the firstyear of the study in the entire population and 92 percent inthe second year among the 3745 subjects who received the thirdinjection. The vaccine was well tolerated. There was a higherincidence of mild, self-limited local and systemic reactionsin the vaccine group, but only during the seven days after vaccination.There was no significant increase in the frequency of arthritisor neurologic events in vaccine recipients.
Conclusions In this study, OspA vaccine was safe and effectivein the prevention of Lyme disease.
Source Information
From the Departments of Medicine, Pediatrics, and Molecular Genetics and Microbiology, University of Medicine and Dentistry of New JerseyRobert Wood Johnson Medical School, New Brunswick (L.H.S., S.J.P.); Pasteur Mérieux Connaught, Swiftwater, Pa. (J.M.Z.); Boston Biostatistics, Boston (P.L.); Gundersen Medical Foundation, LaCrosse, Wis. (G.B.); the Marshfield Clinic, Marshfield, Wis. (R.H.); the Long Island Jewish Medical Center, New Hyde Park, N.Y., and Albert Einstein College of Medicine, New York (E.H.); Danbury Hospital, Danbury, Conn. (M.K.); Stamford Hospital, Stamford, Conn. (D.A.-K.); Southeastern Connecticut Medical Associates, Old Saybrook (T.D.); and the Yale University School of Medicine, New Haven, Conn. (J.E., S.E.M.).
Address reprint requests to Dr. Sigal at 1 Robert Wood Johnson Pl., MEB 484, New Brunswick, NJ 08903-0019.
Immunization against Lyme Disease
Hayes E. B., Dennis D. T., Luger S., Anderson J. R., Steere A. C., Parenti D. L., Krause D. S., Sigal L. H., Zahradnik J., Weinstein A.
Extract |
Full Text
N Engl J Med 1998;
339:1637-1639, Nov 26, 1998.
Correspondence
This article has been cited by other articles:
Hazlett, K. R. O., Caldon, S. D., McArthur, D. G., Cirillo, K. A., Kirimanjeswara, G. S., Magguilli, M. L., Malik, M., Shah, A., Broderick, S., Golovliov, I., Metzger, D. W., Rajan, K., Sellati, T. J., Loegering, D. J.
(2008). Adaptation of Francisella tularensis to the Mammalian Environment Is Governed by Cues Which Can Be Mimicked In Vitro. Infect. Immun.
76: 4479-4488
[Abstract][Full Text]
Ruckdeschel, E. A., Kirkham, C., Lesse, A. J., Hu, Z., Murphy, T. F.
(2008). Mining the Moraxella catarrhalis Genome: Identification of Potential Vaccine Antigens Expressed during Human Infection. Infect. Immun.
76: 1599-1607
[Abstract][Full Text]
Nardelli, D. T., Callister, S. M., Schell, R. F.
(2008). Lyme Arthritis: Current Concepts and a Change in Paradigm. CVI
15: 21-34
[Full Text]
Behera, A. K., Hildebrand, E., Uematsu, S., Akira, S., Coburn, J., Hu, L. T.
(2006). Identification of a TLR-Independent Pathway for Borrelia burgdorferi-Induced Expression of Matrix Metalloproteinases and Inflammatory Mediators through Binding to Integrin {alpha}3beta1. J. Immunol.
177: 657-664
[Abstract][Full Text]
Steere, A. C., Klitz, W., Drouin, E. E., Falk, B. A., Kwok, W. W., Nepom, G. T., Baxter-Lowe, L. A.
(2006). Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. JEM
203: 961-971
[Abstract][Full Text]
Munson, E. L., Nardelli, D. T., Luk, K. H. K., Remington, M. C., Callister, S. M., Schell, R. F.
(2006). Interleukin-6 Promotes Anti-OspA Borreliacidal Antibody Production In Vitro. CVI
13: 19-25
[Abstract][Full Text]
Offit, P. A.
(2005). Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?. Health Aff (Millwood)
24: 622-630
[Abstract][Full Text]
Becker, M., Bunikis, J., Lade, B. D., Dunn, J. J., Barbour, A. G., Lawson, C. L.
(2005). Structural Investigation of Borrelia burgdorferi OspB, a BactericidalFab Target. J. Biol. Chem.
280: 17363-17370
[Abstract][Full Text]
Willett, T. A., Meyer, A. L., Brown, E. L., Huber, B. T.
(2004). An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc. Natl. Acad. Sci. USA
101: 1303-1308
[Abstract][Full Text]
Schroder, N. W. J., Schombel, U., Heine, H., Gobel, U. B., Zahringer, U., Schumann, R. R.
(2003). Acylated Cholesteryl Galactoside as a Novel Immunogenic Motif in Borrelia burgdorferi Sensu Stricto. J. Biol. Chem.
278: 33645-33653
[Abstract][Full Text]
Gilmore, R. D. Jr, Bacon, R. M., Carpio, A. M., Piesman, J., Dolan, M. C., Mbow, M. L.
(2003). Inability of outer-surface protein C (OspC)-primed mice to elicit a protective anamnestic immune response to a tick-transmitted challenge of Borrelia burgdorferi. J Med Microbiol
52: 551-556
[Abstract][Full Text]
Offit, P. A., Hackett, C. J.
(2003). Addressing Parents' Concerns: Do Vaccines Cause Allergic or Autoimmune Diseases?. Pediatrics
111: 653-659
[Abstract][Full Text]
Munson, E. L., Du Chateau, B. K., Jensen, J. R., Callister, S. M., DeCoster, D. J., Schell, R. F.
(2002). Gamma Interferon Inhibits Production of Anti-OspA Borreliacidal Antibody In Vitro. CVI
9: 1095-1101
[Abstract][Full Text]
Ulbrandt, N. D., Cassatt, D. R., Patel, N. K., Roberts, W. C., Bachy, C. M., Fazenbaker, C. A., Hanson, M. S.
(2001). Conformational Nature of the Borrelia burgdorferi Decorin Binding Protein A Epitopes That Elicit Protective Antibodies. Infect. Immun.
69: 4799-4807
[Abstract][Full Text]
Remington, M. C., Munson, E. L., Callister, S. M., Molitor, M. L., Christopherson, J. A., DeCoster, D. J., Lovrich, S. D., Schell, R. F.
(2001). Interleukin-6 Enhances Production of Anti-OspC Immunoglobulin G2b Borreliacidal Antibody. Infect. Immun.
69: 4268-4275
[Abstract][Full Text]
Sikand, V. K., Halsey, N., Krause, P. J., Sood, S. K., Geller, R., Van Hoecke, C., Buscarino, C., Parenti, D., for the Pediatric Lyme Vaccine Study Group,
(2001). Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics
108: 123-128
[Abstract][Full Text]
Pal, U., Montgomery, R. R., Lusitani, D., Voet, P., Weynants, V., Malawista, S. E., Lobet, Y., Fikrig, E.
(2001). Inhibition of Borrelia burgdorferi-Tick Interactions In Vivo by Outer Surface Protein A Antibody. J. Immunol.
166: 7398-7403
[Abstract][Full Text]
Mbow, M. L., Zeidner, N., Gilmore, R. D. Jr., Dolan, M., Piesman, J., Titus, R. G.
(2001). Major Histocompatibility Complex Class II-Independent Generation of Neutralizing Antibodies against T-Cell-Dependent Borrelia burgdorferi Antigens Presented by Dendritic Cells: Regulation by NK and {gamma}{delta} T Cells. Infect. Immun.
69: 2407-2415
[Abstract][Full Text]
Ornstein, K., Berglund, J., Nilsson, I., Norrby, R., Bergström, S.
(2001). Characterization of Lyme Borreliosis Isolates from Patients with Erythema Migrans and Neuroborreliosis in Southern Sweden. J. Clin. Microbiol.
39: 1294-1298
[Abstract][Full Text]
Labandeira-Rey, M., Baker, E. A., Skare, J. T.
(2001). VraA (BBI16) Protein of Borrelia burgdorferi Is a Surface-Exposed Antigen with a Repetitive Motif That Confers Partial Protection against Experimental Lyme Borreliosis. Infect. Immun.
69: 1409-1419
[Abstract][Full Text]
Shadick, N. A., Liang, M. H., Phillips, C. B., Fossel, K., Kuntz, K. M.
(2001). The Cost-effectiveness of Vaccination Against Lyme Disease. Arch Intern Med
161: 554-561
[Abstract][Full Text]
Kouzmitcheva, G. A., Petrenko, V. A., Smith, G. P.
(2001). Identifying Diagnostic Peptides for Lyme Disease through Epitope Discovery. CVI
8: 150-160
[Abstract][Full Text]
Shang, E. S., Wu, X.-y., Lovett, M. A., Miller, J. N., Blanco, D. R.
(2001). Homologous and Heterologous Borrelia burgdorferi Challenge of Infection-Derived Immune Rabbits Using Host-Adapted Organisms. Infect. Immun.
69: 593-598
[Abstract][Full Text]
Parenti, D. L., Schell, R. F., Callister, S. M., Lovrich, S. D.
(2000). Outer Surface Protein A and Arthritis in Hamsters. Infect. Immun.
68: 7212-7213
[Full Text]
Damman, C. J., Eggers, C. H., Samuels, D. S., Oliver, D. B.
(2000). Characterization of Borrelia burgdorferi BlyA and BlyB Proteins: a Prophage-Encoded Holin-Like System. J. Bacteriol.
182: 6791-6797
[Abstract][Full Text]
Hanson, M. S., Patel, N. K., Cassatt, D. R., Ulbrandt, N. D.
(2000). Evidence for Vaccine Synergy between Borrelia burgdorferi Decorin Binding Protein A and Outer Surface Protein A in the Mouse Model of Lyme Borreliosis. Infect. Immun.
68: 6457-6460
[Abstract][Full Text]
Munson, E. L., Du Chateau, B. K., Jobe, D. A., Lovrich, S. D., Callister, S. M., Schell, R. F.
(2000). Production of Borreliacidal Antibody to Outer Surface Protein A In Vitro and Modulation by Interleukin-4. Infect. Immun.
68: 5496-5501
[Abstract][Full Text]
Hagman, K. E., Yang, X., Wikel, S. K., Schoeler, G. B., Caimano, M. J., Radolf, J. D., Norgard, M. V.
(2000). Decorin-Binding Protein A (DbpA) of Borrelia burgdorferi Is Not Protective When Immunized Mice Are Challenged via Tick Infestation and Correlates with the Lack of DbpA Expression by B. burgdorferi in Ticks. Infect. Immun.
68: 4759-4764
[Abstract][Full Text]
Shang, E. S., Champion, C. I., Wu, X.-Y., Skare, J. T., Blanco, D. R., Miller, J. N., Lovett, M. A.
(2000). Comparison of Protection in Rabbits against Host-Adapted and Cultivated Borrelia burgdorferi following Infection-Derived Immunity or Immunization with Outer Membrane Vesicles or Outer Surface Protein A. Infect. Immun.
68: 4189-4199
[Abstract][Full Text]
Malawista, S. E., Montgomery, R. R., Wang, X.-M., Fu, L. L., Giles, S. S.
(2000). Geographic clustering of an outer surface protein A mutant of Borrelia burgdorferi. Possible implications of multiple variants for Lyme disease persistence. Rheumatology (Oxford)
39: 537-541
[Abstract][Full Text]
Thanassi, W. T., Schoen, R. T.
(2000). The Lyme Disease Vaccine: Conception, Development, and Implementation. ANN INTERN MED
132: 661-668
[Abstract][Full Text]
Croke, C. L., Munson, E. L., Lovrich, S. D., Christopherson, J. A., Remington, M. C., England, D. M., Callister, S. M., Schell, R. F.
(2000). Occurrence of Severe Destructive Lyme Arthritis in Hamsters Vaccinated with Outer Surface Protein A and Challenged with Borrelia burgdorferi. Infect. Immun.
68: 658-663
[Abstract][Full Text]
Katona, L. I., Ayalew, S., Coleman, J. L., Benach, J. L.
(2000). A Bactericidal Monoclonal Antibody Elicits a Change in Its Antigen, OspB of Borrelia burgdorferi, That Can Be Detected by Limited Proteolysis. J. Immunol.
164: 1425-1431
[Abstract][Full Text]
Chang, Y.-F., McDonough, S. P., Chang, C.-F., Shin, K.-S., Yen, W., Divers, T.
(2000). Human Granulocytic Ehrlichiosis Agent Infection in a Pony Vaccinated with a Borrelia burgdorferi Recombinant OspA Vaccine and Challenged by Exposure to Naturally Infected Ticks. CVI
7: 68-71
[Abstract][Full Text]
Wieneke, C. A., Lovrich, S. D., Callister, S. M., Jobe, D. A., Marks, J. A., Schell, R. F.
(2000). Evaluation of Whole-Cell and OspC Enzyme-Linked Immunosorbent Assays for Discrimination of Early Lyme Borreliosis from OspA Vaccination. J. Clin. Microbiol.
38: 313-317
[Abstract][Full Text]
Committee on Infectious Diseases,
(2000). Prevention of Lyme Disease. Pediatrics
105: 142-147
[Abstract][Full Text]
Albert, L. J., Inman, R. D.
(1999). Molecular Mimicry and Autoimmunity. NEJM
341: 2068-2074
[Full Text]
Marconi, R. T., Hohenberger, S., Jauris-Heipke, S., Schulte-Spechtel, U., LaVoie, C. P., Rößler, D., Wilske, B.
(1999). Genetic Analysis of Borrelia garinii OspA Serotype 4 Strains Associated with Neuroborreliosis: Evidence for Extensive Genetic Homogeneity. J. Clin. Microbiol.
37: 3965-3970
[Abstract][Full Text]
Liang, F. T., Steere, A. C., Marques, A. R., Johnson, B. J. B., Miller, J. N., Philipp, M. T.
(1999). Sensitive and Specific Serodiagnosis of Lyme Disease by Enzyme-Linked Immunosorbent Assay with a Peptide Based on an Immunodominant Conserved Region of Borrelia burgdorferi VlsE. J. Clin. Microbiol.
37: 3990-3996
[Abstract][Full Text]
Lawrenz, M. B., Hardham, J. M., Owens, R. T., Nowakowski, J., Steere, A. C., Wormser, G. P., Norris, S. J.
(1999). Human Antibody Responses to VlsE Antigenic Variation Protein of Borrelia burgdorferi. J. Clin. Microbiol.
37: 3997-4004
[Abstract][Full Text]
Schutzer, S. E., Coyle, P. K., Reid, P., Holland, B.
(1999). Borrelia burgdorferi-Specific Immune Complexes in Acute Lyme Disease. JAMA
282: 1942-1946
[Abstract][Full Text]
Jobe, D. A., Rawal, N., Schell, R. F., Callister, S. M.
(1999). Detection of Borreliacidal Antibodies in Lyme Borreliosis Patient Sera Containing Antimicrobial Agents. CVI
6: 930-933
[Abstract][Full Text]
Wang, G., van Dam, A. P., Schwartz, I., Dankert, J.
(1999). Molecular Typing of Borrelia burgdorferi Sensu Lato: Taxonomic, Epidemiological, and Clinical Implications. Clin. Microbiol. Rev.
12: 633-653
[Abstract][Full Text]
Gilmore, R. D. Jr., Mbow, M. L.
(1999). Conformational Nature of the Borrelia burgdorferi B31 Outer Surface Protein C Protective Epitope. Infect. Immun.
67: 5463-5469
[Abstract][Full Text]
Skare, J. T., Foley, D. M., Hernandez, S. R., Moore, D. C., Blanco, D. R., Miller, J. N., Lovett, M. A.
(1999). Cloning and Molecular Characterization of Plasmid-Encoded Antigens of Borrelia burgdorferi. Infect. Immun.
67: 4407-4417
[Abstract][Full Text]
Brown, S. L., Hansen, S. L., Langone, J. J.
(1999). Role of Serology in the Diagnosis of Lyme Disease. JAMA
282: 62-66
[Abstract][Full Text]
Seinost, G., Dykhuizen, D. E., Dattwyler, R. J., Golde, W. T., Dunn, J. J., Wang, I.-N., Wormser, G. P., Schriefer, M. E., Luft, B. J.
(1999). Four Clones of Borrelia burgdorferi Sensu Stricto Cause Invasive Infection in Humans. Infect. Immun.
67: 3518-3524
[Abstract][Full Text]
Bunikis, J., Barbour, A. G.
(1999). Access of Antibody or Trypsin to an Integral Outer Membrane Protein (P66) of Borrelia burgdorferi Is Hindered by Osp Lipoproteins. Infect. Immun.
67: 2874-2883
[Abstract][Full Text]
Nowling, J. M., Philipp, M. T.
(1999). Killing of Borrelia burgdorferi by Antibody Elicited by OspA Vaccine Is Inefficient in the Absence of Complement. Infect. Immun.
67: 443-445
[Abstract][Full Text]
Hayes, E. B., Dennis, D. T., Luger, S., Anderson, J. R., Steere, A. C., Parenti, D. L., Krause, D. S., Sigal, L. H., Zahradnik, J., Weinstein, A.
(1998). Immunization against Lyme Disease. NEJM
339: 1637-1639
[Full Text]
(1998). A Vaccine Against Lyme Disease. Journal Watch Dermatology
1998: 8-8
[Full Text]
(1998). Vaccine Holds Promise for Lyme Disease. JWatch General
1998: 1-1
[Full Text]
Steigbigel, R. T., Benach, J. L.
(1998). Immunization against Lyme Disease -- An Important First Step. NEJM
339: 263-264
[Full Text]
Hellwage, J., Meri, T., Heikkila, T., Alitalo, A., Panelius, J., Lahdenne, P., Seppala, I. J. T., Meri, S.
(2001). The Complement Regulator Factor H Binds to the Surface Protein OspE of Borrelia burgdorferi. J. Biol. Chem.
276: 8427-8435
[Abstract][Full Text]